CNOT7 and liver cancer: For instance, in hepatic cancer cells (i.e., HepG2), the AKT inhibitor triciribine triggers the ERK/RSK1 pathway, which phosphorylates BRF1 and reduces its binding to CNOT7, thereby increasing the stability of low-density lipoprotein receptor mRNAs [76].